SciBase completes share issue, raising approximately SEK 57.5 million
Medical diagnostics company SciBase Holding AB announced the outcome of its rights issue. The company successfully raised approximately SEK 57.5 million before issue costs, with funds earmarked for continued commercialization efforts, particularly in the United States market.
Stockholm – SciBase Holding AB has concluded its rights issue, successfully raising approximately SEK 57.5 million before accounting for issue costs. The subscription period for the issue, which aimed to secure capital for the company's operations, ended on September 29, 2026.
According to the company's announcement, approximately 73.4 percent of the issue was subscribed for either with or without subscription rights. The remaining 26.6 percent was guaranteed by Bergs Securities AB, ensuring the rights issue was fully subscribed. SciBase will receive approximately SEK 57.5 million, with estimated issue costs of SEK 4.8 million.
The capital infusion is intended to support SciBase's ongoing commercialization activities, with a strategic focus on expanding its presence and operations within the United States market. The company is engaged in melanoma diagnostics and is nearing a significant milestone related to reimbursement in the U.S.
"We are very grateful for the confidence that shareholders and new investors have shown in us," stated CEO Pia Renaudin. "The raised capital enables the company to continue to build its position in melanoma diagnostics in the United States."
Jesper Høiland, Chairman of the Board, added that the broad support from shareholders signifies strength. He noted that with strengthened finances and a well-performing organization in both the U.S. and Germany, SciBase is well-positioned for its next phase, including an upcoming CEO transition.